# A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07491458** · PHASE2 · RECRUITING · sponsor: **Rivus Pharmaceuticals, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- MASH - Metabolic Dysfunction-Associated Steatohepatitis

## Interventions

- **DRUG:** HU6
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07491458
- **Lead sponsor:** Rivus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-13
- **Primary completion:** 2027-02
- **Final completion:** 2028-02
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07491458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07491458, "A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07491458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*